AKI is a common medical condition and results in hospital complication in critically ill patients. Its incidence among intensive care unit (ICU) patients has been reported to range between 16-67%. AKI is associated with poor prognosis, extensive morbidity, increased short term and long term mortality and significant health care expenditures. AKI is one of the most serious and common health complications and in the critical care setting (ICU) AKI is associated with a mortality rate of 60%. Despite advances in supportive care, mortality rates associated with AKI remain high.
Atox Bio developed robust data from animal models. Initial data suggest that Reltecimod provides a treatment benefit (improved renal function and recovery from AKI) in a subset of patients from the phase 2 NSTI study, characterized as suffering from AKI as part of the disease process.